10-Q: Bio-Techne Reports 5% Revenue Increase but Net Earnings Decline in Q1 2025

Bio-Techne Corporation saw a 5% increase in net sales but a decrease in net earnings for the quarter ended September 30, 2024, compared to the same period last year.

Summary

• Bio-Techne Corporation reported a 5% increase in net sales, reaching $289.5 million for the quarter ended September 30, 2024, compared to $276.9 million in the same period last year.
• Organic growth was 4%, with foreign currency exchange impacting sales by approximately 1%.
• Net earnings decreased to $33.6 million, down from $51.0 million in the same quarter of the previous year.
• The company's gross margin was 63.2%, a decrease from 66.9% in the prior year, with adjusted gross margin at 69.5% compared to 71.3%.
• Selling, general, and administrative expenses increased by 13% to $119.2 million, primarily due to restructuring costs.
• Research and development expenses decreased slightly by 1% to $23.9 million.
• The Protein Sciences segment's net sales remained flat at $204.5 million, while the Diagnostics and Spatial Biology segment saw a 14% increase in net sales to $83.2 million.
• The company's effective income tax rate was 16.4%, compared to (2.9)% in the same quarter of the previous year.
• Cash and cash equivalents and available-for-sale investments totaled $187.5 million as of September 30, 2024, up from $152.9 million as of June 30, 2024.
• The company invested $15 million in Spear Bio during the quarter.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While revenue increased, the significant drop in net earnings and gross margin raises concerns. The restructuring efforts and legal matters add to the uncertainty. However, the company's strategic investments and growth in the Diagnostics and Spatial Biology segment are positive signs.

Positives

• Net sales increased by 5% year-over-year.
• The Diagnostics and Spatial Biology segment showed strong growth with a 14% increase in net sales.
• Organic revenue growth was 4% for the quarter.
• Cash and cash equivalents increased to $187.5 million from $152.9 million at the end of the previous quarter.
• The company has $700 million available on its line of credit.

Negatives

• Net earnings decreased significantly from $51.0 million to $33.6 million year-over-year.
• Gross margin decreased from 66.9% to 63.2%.
• Selling, general, and administrative expenses increased by 13% due to restructuring costs.
• The Protein Sciences segment's net sales remained flat compared to the same period last year.

Risks

• The company is undergoing restructuring actions that are expected to incur costs through fiscal 2026.
• The company is involved in legal actions, the outcomes of which are not within the company's complete control and could have a material adverse impact.
• The company's future gross margins are expected to be impacted by the mix of the portfolio growing at different rates and future acquisitions.
• The company's effective tax rate can fluctuate due to discrete items.
• The company has a forward contract to acquire the remaining equity of Wilson Wolf for approximately $1 billion plus potential contingent consideration between fiscal 2026 and 2028.

Future Outlook

The company expects its consolidated income tax rate for the remainder of fiscal 2025 to range from 23% to 27%, excluding the impact of discrete items. Capital expenditures for the remainder of fiscal 2025 are expected to be approximately $32 million. Management expects to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future.

Management Comments

• The company is committed to providing the life sciences community with innovative, high-quality scientific tools.
• The company intends to build on past accomplishments, high product quality reputation and sound financial position by executing strategies that position it to serve as the standard for biological content in the research market.
• The company's strategic pillars for long-term growth and profitability are grow and leverage the core, capitalize on high potential markets, market expansion through innovation and acquisition, deliver best-in-class customer experience, and develop people through a transformative culture.

Industry Context

Bio-Techne operates in the biotechnology sector, which is characterized by continuous innovation and competition. The company's focus on both research and clinical diagnostic markets positions it to capitalize on the growing demand for advanced scientific tools and diagnostics. The acquisition of Lunaphore Technologies SA is a strategic move to strengthen its position in the spatial biology market, which is a rapidly growing area within the life sciences industry.

Comparison to Industry Standards

• Bio-Techne's revenue growth of 5% is moderate compared to some high-growth biotech companies, but it is important to consider the company's diversified portfolio and focus on both research and diagnostics.
• The decrease in gross margin from 66.9% to 63.2% is a point of concern, as many biotech companies strive for higher margins. However, the adjusted gross margin of 69.5% indicates that some of the decrease is due to specific accounting adjustments.
• The company's investment in Spear Bio is a common strategy in the biotech industry, where companies often invest in early-stage technologies to expand their product pipeline.
• Compared to companies like Thermo Fisher Scientific and Danaher, Bio-Techne is smaller but has a strong presence in specific niches, such as cytokines and growth factors.
• The restructuring actions are similar to those taken by other companies in the industry to optimize operations and improve profitability.

Legal Proceedings

• The company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations.
• In August 2024, 804,162 shares of outstanding vested stock options related to former employees expired which have now been excluded from the Companys dilutive EPS calculation for the period ended September 30, 2024. The expiration date of these options is currently under dispute.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net earnings and gross margin.
• Employees may be affected by the ongoing restructuring actions.
• Customers may benefit from the company's continued investment in innovative products and services.
• Suppliers may be impacted by changes in the company's operations and supply chain.
• Creditors may be interested in the company's cash flow and debt management.

Next Steps

• The company will continue to execute its restructuring plan through fiscal 2026.
• The company will continue to monitor and manage its legal proceedings.
• The company will continue to invest in capital expenditures to meet expected sales growth.
• The company will pay a cash dividend of $0.08 per share on November 22, 2024.

Key Dates

Keywords

Bio-Techne, biotechnology, reagents, instruments, diagnostics, spatial biology, protein sciences, net sales, net earnings, gross margin, restructuring, acquisitions